NASDAQ:RKDA Arcadia Biosciences (RKDA) Stock Price, News & Analysis $0.22 0.00 (0.00%) As of 11/13/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsSEC Filings About Arcadia Biosciences Stock (NASDAQ:RKDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcadia Biosciences alerts:Sign Up Key Stats Today's Range$0.18▼$0.2350-Day Range$0.15▼$0.4852-Week Range$0.11▼$3.87Volume679,429 shsAverage Volume1.63 million shsMarket Capitalization$525.38 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Arcadia Biosciences, Inc. is an agricultural biotechnology company focused on developing and commercializing food ingredients and crop-based products intended to support health and wellness. The company applies plant science and breeding technologies to develop crops with enhanced nutritional characteristics and products designed for consumer and food-industry applications. Its product portfolio has included GoodWheat, a wheat variety developed with increased dietary fiber and other nutritional attributes, as well as GoodHemp, a line of hemp-based food products and ingredients. Arcadia has also pursued additional crop and ingredient technologies addressing areas such as improved nutrition, sustainability and agricultural productivity. Founded in 2002 and headquartered in Davis, California, Arcadia has historically operated through research, product development, licensing and commercialization activities in the agricultural and food sectors. Its products and technologies have been marketed primarily in the United States, with potential applications for broader food and agricultural markets.AI Generated. May Contain Errors. Read More Arcadia Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreRKDA MarketRank™: 1.066016602975 of 5 starsArcadia Biosciences scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingArcadia Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageArcadia Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Arcadia Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.02% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 0.15, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 66.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. News and Social Media4.0 / 5News Sentiment1.45 News SentimentArcadia Biosciences has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Arcadia Biosciences this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Arcadia Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.50% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by Institutions17.73% of the stock of Arcadia Biosciences is held by institutions.Read more about Arcadia Biosciences' insider trading history. Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RKDA Stock News HeadlinesArcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business HighlightsNovember 12, 2026 | globenewswire.comArcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business HighlightsAugust 13, 2026 | globenewswire.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. | Weiss Ratings (Ad)RKDA Share News TodayJuly 6, 2026 | uk.investing.comArcadia Biosciences, Inc.: Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesJune 13, 2026 | finanznachrichten.deArcadia Biosciences, Inc. Closes $4 Million Private Placement of Common Stock and Preferred Investment OptionsJune 12, 2026 | quiverquant.comQArcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesJune 12, 2026 | globenewswire.comArcadia Biosciences, Inc. Announces Private Placement of Common Stock and Preferred Investment Options to Raise Approximately $4 MillionJune 11, 2026 | quiverquant.comQSee More Headlines RKDA Stock Analysis - Frequently Asked Questions How have RKDA shares performed this year? Arcadia Biosciences' stock was trading at $1.98 at the start of the year. Since then, RKDA stock has decreased by 89.0% and is now trading at $0.2180. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) released its earnings results on Thursday, November, 12th. The basic materials company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.75. The basic materials company earned $1.62 million during the quarter, compared to analyst estimates of $2.40 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 203.20% and a negative net margin of 202.09%. When did Arcadia Biosciences' stock split? Shares of Arcadia Biosciences reverse split on the morning of Wednesday, January 24th 2018.The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Arcadia Biosciences IPO? Arcadia Biosciences (RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO. How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcadia Biosciences investors own include Micron Technology (MU), NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), NIO (NIO), Sorrento Therapeutics (SRNE) and Aurora Cannabis (ACB). Company Calendar Last Earnings11/12/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 RKDA's financial health is in the Red zone, according to TradeSmith. RKDA has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Staples Industry Beverages Sub-IndustrySoft Drinks & Non-alcoholic Beverages Current SymbolNASDAQ:RKDA CIK1469443 Webwww.arcadiabio.com Phone(214) 974-8921Fax530-756-7027Employees8Year Founded2002Profitability EPS (Trailing Twelve Months)($4.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.34 million Net Margins-202.09% Pretax Margin-201.94% Return on Equity-203.20% Return on Assets-90.95% Debt Debt-to-Equity RatioN/A Current Ratio3.58 Quick Ratio2.82 Sales & Book Value Annual Sales$4.86 million Price / Sales0.11 Cash Flow$1.28 per share Price / Cash Flow0.17 Book Value$2.39 per share Price / Book0.09Miscellaneous Outstanding Shares2,410,000Free Float2,301,000Market Cap$525.38 thousand OptionableNot Optionable Beta0.63 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:RKDA) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredGlobal Industrial Powerhouse Taps Nasdaq Drone MicrocapA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredATTENTION: Elon’s silent partnerElon Musk's plan to take AI beyond Earth and put data centers into orbit is what Tim Bohen calls Mission X. Hi...Millionaire Pub | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcadia Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.